Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Journal of Translational Medicine · 2024
DOI: 10.1186/s12967-024-05049-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Translational Medicine, 2024. Verfasst von Neshat Saffarzadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, Intervention and Technology, Karolinska Institutet, ANA Futura, Alfred Nobels Allé 8, 141 52, Huddinge, Stockholm, Sw…. Hauptthemen laut MEDLINE: Oncolytic Viruses, Neoplasms, Oncolytic Virotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Barncancerfonden.
Abstract (Originalsprache)
Background
Intratumoral injection of oncolytic viruses (OVs) shows promise in immunotherapy: ONCOS-102, a genetically engineered OV that encodes Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF) demonstrated efficacy in early clinical trials, enhancing T cell infiltration in tumors. This suggests OVs may boost various forms of immunotherapy, including tumor-specific bi-specific antibodies (BsAbs).
Methods
Our study investigated in vitro, how ONCOS-204, a variant of ONCOS-virus expressing the ligand of inducible T-cell co-stimulator (ICOSL), modulates the process of T cell activation induced by a BsAb. ONCOS-102 was used for comparison. Phenotypic and functional changes induced by combination of different OVs, and BsAb in T cell subsets were assessed by flow cytometry, viability, and proliferation assays.
Results
Degranulation and IFNγ and TNF production of T cells, especially CD4 + T cells was the most increased upon target cell exposure to ONCOS-204. Unexpectedly, ONCOS-204 profoundly affected CD8 + T cell proliferation and function through ICOS-L/ICOS interaction. The effect solely depended on cell surface expression of ICOS-L as soluble ICOSL did not induce notable T cell activity.
Conclusions
Together, our data suggests that oncolytic adenoviruses encoding ICOSL may enhance functional activity of tumor-specific BsAbs thereby opening a novel avenue for clinical development in immunotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science, Intervention and Technology, Karolinska Institutet, ANA Futura, Alfred Nobels Allé 8, 141 52, Huddinge, Stockholm, Sweden.
- Circio AB, Stockholm, Sweden.
- Department of Clinical Science, Intervention and Technology, Karolinska Institutet, ANA Futura, Alfred Nobels Allé 8, 141 52, Huddinge, Stockholm, Sweden. thomas.poiret@ki.se.
- Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Thomas Poiret
Förderung
- Vetenskapsrådet
- Cancerfonden
- Barncancerfonden
- Radiumhemmets Forskningsfonder
- Knut och Alice Wallenbergs Stiftelse
- Karolinska Institute
Zitieren
APA
Saffarzadeh, N., Foord, E., O'Leary, E., Mahmoun, R., Birkballe Hansen, T., Levitsky, V., Poiret, T., & Uhlin, M. (2024). Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-05049-2
Vancouver
Saffarzadeh N, Foord E, O'Leary E, Mahmoun R, Birkballe Hansen T, Levitsky V, et al. Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy. Journal of Translational Medicine. 2024. doi:10.1186/s12967-024-05049-2
BibTeX
@article{Saffarzadeh2024,
author = {Saffarzadeh, Neshat and Foord, Emelie and O'Leary, Eoghan and Mahmoun, Rand and Birkballe Hansen, Thomas and Levitsky, Victor and Poiret, Thomas and Uhlin, Michael},
title = {Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy},
journal = {Journal of Translational Medicine},
year = {2024},
doi = {10.1186/s12967-024-05049-2}
}
EUVIMED